FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096002562> ?p ?o ?g. }

• W3096002562 endingPage "104380" @default.
• W3096002562 startingPage "104380" @default.
• W3096002562 abstract "Sixteen novel quinazoline-based derivatives were designed and synthesized via modification of the VEGFR-2 reported inhibitor 7 in order to increase the binding affinity of the designed compounds to the receptor active site. The designed compounds were evaluated for their VEGFR-2 inhibitory effects. Inhibiting VEGFR-2 has been set up as a therapeutic strategy for treatment of cancer. The bioactivity of the new compounds was performed against HepG-2, MCF-7 and HCT-116 cell lines. Doxorubicin and sorafenib were used as positive controls. Compound 18d was observed to have promising cytotoxic activity (IC50 = 3.74 ± 0.14, 5.00 ± 0.20 and 6.77 ± 0.27 µM) in comparison to the reference drug doxorubicin (IC50 = 8.28, 9.63 and 7.67 µM) and sorafenib (IC50 = 7.31, 9.40 and 7.21 µM). The most active compounds were tested for their in vitro VEGFR-2 inhibitory activities. Results of VEGFR-2 inhibition were consistent with that of the cytotoxicity data. Thus, compound 18d showed VEGFR-2 inhibitory activity (IC50 = 0.340 ± 0.04 µM) superior to that of the reference drug, sorafenib (IC50 = 0.588 ± 0.06 µM). Furthermore, docking study was performed in order to understand the binding pattern of the new compounds into VEGFR-2 active site. Docking results attributed the potent VEGFR-2 inhibitory effect of the new compounds as they bound to the key amino acids in the active site, Glu883 and Asp1044, as well as their hydrophobic interaction with the receptor hydrophobic pocket. Results of cytotoxic activities, in vitro VEGFR-2 inhibition together with docking study argument the advantages of the synthesized analogues as promising anti-angiogenic agents." @default.
• W3096002562 created "2020-11-09" @default.
• W3096002562 creator A5005100115 @default.
• W3096002562 creator A5010485820 @default.
• W3096002562 creator A5020589815 @default.
• W3096002562 creator A5029891269 @default.
• W3096002562 creator A5035057631 @default.
• W3096002562 creator A5044030554 @default.
• W3096002562 creator A5046094471 @default.
• W3096002562 creator A5055998450 @default.
• W3096002562 creator A5066270766 @default.
• W3096002562 creator A5081659763 @default.
• W3096002562 creator A5088150567 @default.
• W3096002562 date "2020-12-01" @default.
• W3096002562 modified "2023-09-27" @default.
• W3096002562 title "Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation" @default.
• W3096002562 cites W1629179716 @default.
• W3096002562 cites W1980251946 @default.
• W3096002562 cites W1984316153 @default.
• W3096002562 cites W2000000541 @default.
• W3096002562 cites W2018711732 @default.
• W3096002562 cites W2038705515 @default.
• W3096002562 cites W2052178182 @default.
• W3096002562 cites W2063302127 @default.
• W3096002562 cites W2065445082 @default.
• W3096002562 cites W2079398727 @default.
• W3096002562 cites W2093258518 @default.
• W3096002562 cites W2093579635 @default.
• W3096002562 cites W2097373408 @default.
• W3096002562 cites W2114918609 @default.
• W3096002562 cites W2143926802 @default.
• W3096002562 cites W2147107643 @default.
• W3096002562 cites W2150048971 @default.
• W3096002562 cites W2155436552 @default.
• W3096002562 cites W2166689953 @default.
• W3096002562 cites W2312594601 @default.
• W3096002562 cites W2395523735 @default.
• W3096002562 cites W2538465384 @default.
• W3096002562 cites W2576376115 @default.
• W3096002562 cites W2609237181 @default.
• W3096002562 cites W2733930358 @default.
• W3096002562 cites W2744624393 @default.
• W3096002562 cites W2749897366 @default.
• W3096002562 cites W2769328077 @default.
• W3096002562 cites W2785579854 @default.
• W3096002562 cites W2796152634 @default.
• W3096002562 cites W2805634574 @default.
• W3096002562 cites W2808351871 @default.
• W3096002562 cites W2940507061 @default.
• W3096002562 cites W2952405585 @default.
• W3096002562 cites W2958973731 @default.
• W3096002562 cites W2970220863 @default.
• W3096002562 cites W2979647576 @default.
• W3096002562 cites W2988361120 @default.
• W3096002562 cites W3000738750 @default.
• W3096002562 cites W3081848457 @default.
• W3096002562 doi "https://doi.org/10.1016/j.bioorg.2020.104380" @default.
• W3096002562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33128967" @default.
• W3096002562 hasPublicationYear "2020" @default.
• W3096002562 type Work @default.
• W3096002562 sameAs 3096002562 @default.
• W3096002562 citedByCount "57" @default.
• W3096002562 countsByYear W30960025622021 @default.
• W3096002562 countsByYear W30960025622022 @default.
• W3096002562 countsByYear W30960025622023 @default.
• W3096002562 crossrefType "journal-article" @default.
• W3096002562 hasAuthorship W3096002562A5005100115 @default.
• W3096002562 hasAuthorship W3096002562A5010485820 @default.
• W3096002562 hasAuthorship W3096002562A5020589815 @default.
• W3096002562 hasAuthorship W3096002562A5029891269 @default.
• W3096002562 hasAuthorship W3096002562A5035057631 @default.
• W3096002562 hasAuthorship W3096002562A5044030554 @default.
• W3096002562 hasAuthorship W3096002562A5046094471 @default.
• W3096002562 hasAuthorship W3096002562A5055998450 @default.
• W3096002562 hasAuthorship W3096002562A5066270766 @default.
• W3096002562 hasAuthorship W3096002562A5081659763 @default.
• W3096002562 hasAuthorship W3096002562A5088150567 @default.
• W3096002562 hasConcept C109316439 @default.
• W3096002562 hasConcept C141071460 @default.
• W3096002562 hasConcept C159110408 @default.
• W3096002562 hasConcept C181199279 @default.
• W3096002562 hasConcept C185592680 @default.
• W3096002562 hasConcept C202751555 @default.
• W3096002562 hasConcept C2776694085 @default.
• W3096002562 hasConcept C2777752497 @default.
• W3096002562 hasConcept C2778019345 @default.
• W3096002562 hasConcept C2778695046 @default.
• W3096002562 hasConcept C2778866207 @default.
• W3096002562 hasConcept C2781303535 @default.
• W3096002562 hasConcept C41183919 @default.
• W3096002562 hasConcept C41685203 @default.
• W3096002562 hasConcept C502942594 @default.
• W3096002562 hasConcept C55493867 @default.
• W3096002562 hasConcept C71240020 @default.
• W3096002562 hasConcept C71924100 @default.
• W3096002562 hasConcept C86803240 @default.
• W3096002562 hasConcept C98274493 @default.
• W3096002562 hasConceptScore W3096002562C109316439 @default.

• next